Back to Agenda
SESSION 5: SIGNAL DETECTION AND BENEFIT/RISK ASSESSMENT
Session Chair(s)
Shelley Gandhi, MSc
Strategic Advisor, Pharmacovigilance and Drug Safety
NDA Group, United Kingdom
This session will discuss how the QPPV can supervise and be involved in establishing the safety governance processes for signal detection and benefit-risk assessment, be responsible for the adequacy of documentation describing these processes and their tracking and assure compliance. The QPPV is expected to explain best signal detection practices, the rationale for different methodologies and choice of sources for signal detection and how validation should occur.
Speaker(s)
SIGNAL DETECTION AND BENEFIT/RISK ASSESSMENT
Shelley Gandhi, MSc
NDA Group, United Kingdom
Strategic Advisor, Pharmacovigilance and Drug Safety
Have an account?